Acute chest pain (ACP) is a common presenting complaint in emergency departments worldwide, posing a diagnostic challenge for healthcare professionals. This article provides a comprehensive guide for the clinical approach to ACP, emphasizing evidence-based practices and recent advancements.
The initial assessment of a patient presenting with ACP should focus on obtaining a detailed history and performing a thorough physical examination. Key elements include the character, onset, location, duration, and radiation of pain. Associated symptoms, risk factors for cardiovascular disease, and relevant past medical history should also be considered.
The differential diagnosis of ACP is broad, encompassing conditions ranging from benign musculoskeletal pain to life-threatening disorders such as acute coronary syndromes (ACS), pulmonary embolism, and aortic dissection. A high index of suspicion should be maintained for these serious conditions, particularly in patients with risk factors.
Diagnostic testing should be guided by the pretest probability of different conditions. Electrocardiogram (ECG) and cardiac biomarkers are essential for diagnosing ACS. Other tests, such as chest X-ray, computed tomography (CT), or echocardiography, may be indicated based on the suspected differential diagnosis.
The management of ACP varies depending on the underlying cause. Patients with ACS require prompt reperfusion therapy, whereas those with non-cardiac chest pain may benefit from symptomatic treatment and reassurance. All patients should receive risk factor modification and follow-up arrangements.
ACP is a complex clinical entity requiring a systematic approach for effective management. Healthcare professionals must maintain a broad differential diagnosis, utilize appropriate diagnostic testing, and deliver tailored treatment based on the underlying cause. Continued education and adherence to evidence-based guidelines are key to improving patient outcomes in this challenging area.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation